Diagnos Laboratorium Utama PT Tbk DGNS.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

286

-1.38%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in IDR, from our data supplier.

FY2025

Revenue

IDR 166.62bn

FY2017FY2025

Net income

IDR 2.94bn

FY2017FY2025

Free cash flow

IDR 2.58bn

FY2017FY2025

Shareholders' equity

IDR 203.99bn

FY2017FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	IDR 166.62bn	IDR 163.07bn	IDR 145.70bn	IDR 192.89bn	IDR 302.18bn	IDR 183.17bn	IDR 51.34bn	IDR 38.55bn	IDR 14.01bn
Gross profit	IDR 71.61bn	IDR 64.49bn	IDR 59.31bn	IDR 88.40bn	IDR 147.64bn	IDR 85.90bn	IDR 19.49bn	IDR 16.53bn	IDR 4.70bn
Research and development	IDR 857.4m	IDR 759.2m	IDR 249.0m	IDR 586.2m	IDR 273.6m	IDR 593.4m	IDR 425.9m	—	—
Operating income	IDR 5.08bn	IDR 2.22bn	−IDR 14.03bn	IDR 17.66bn	IDR 81.28bn	IDR 67.03bn	IDR 13.20bn	IDR 12.44bn	IDR 1.94bn
Net income	IDR 2.94bn	IDR 747.4m	−IDR 13.66bn	IDR 12.66bn	IDR 64.30bn	IDR 52.69bn	IDR 9.27bn	IDR 9.26bn	IDR 1.38bn
Diluted earnings per share	2.35	0.60	-10.92	10.13	51.44	52.69	17.81	6.19	0.92

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Total assets	IDR 318.67bn	IDR 300.02bn	IDR 271.48bn	IDR 239.94bn	IDR 241.98bn	IDR 132.57bn	IDR 59.22bn	IDR 24.44bn	IDR 8.49bn
Cash and short-term investments	IDR 9.93bn	IDR 5.17bn	IDR 11.94bn	IDR 30.55bn	IDR 51.23bn	IDR 16.54bn	IDR 1.39bn	IDR 1.54bn	IDR 1.30bn
Total liabilities	IDR 114.68bn	IDR 103.89bn	IDR 75.88bn	IDR 29.51bn	IDR 40.18bn	IDR 33.51bn	IDR 12.76bn	IDR 11.17bn	IDR 5.27bn
Debt	IDR 79.25bn	IDR 72.09bn	IDR 56.76bn	IDR 21.47bn	IDR 13.42bn	IDR 2.95bn	IDR 3.69bn	IDR 5.22bn	IDR 112.8m
Shareholders' equity	IDR 203.99bn	IDR 196.13bn	IDR 195.59bn	IDR 210.43bn	IDR 201.80bn	IDR 99.07bn	IDR 46.46bn	IDR 13.27bn	IDR 3.22bn
Shares outstanding	1,250m	1,250m	1,250m	1,250m	1,250m	1,000m	521m	1,498m	1,498m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Cash from operations	IDR 10.66bn	IDR 27.30bn	IDR 13.18bn	−IDR 6.02bn	IDR 58.87bn	IDR 26.23bn	IDR 11.20bn	IDR 8.47bn	−IDR 712.0m
Capital spending	−IDR 8.07bn	−IDR 43.39bn	−IDR 38.32bn	−IDR 34.85bn	−IDR 67.84bn	−IDR 5.86bn	−IDR 2.78bn	−IDR 3.84bn	−IDR 327.5m
Free cash flow	IDR 2.58bn	−IDR 16.10bn	−IDR 25.14bn	−IDR 40.87bn	−IDR 8.97bn	IDR 20.36bn	IDR 8.41bn	IDR 4.63bn	−IDR 1.04bn
Dividends paid	—	—	—	—	−IDR 6.00bn	−IDR 6.00bn	−IDR 6.00bn	−IDR 6.00bn	—

Latest quarters

By quarter end

	Jun 2026	Mar 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024
Revenue	IDR 45.11bn	IDR 41.63bn	IDR 48.35bn	IDR 41.39bn	IDR 39.69bn	IDR 37.20bn	IDR 39.72bn	IDR 42.31bn
Gross profit	IDR 20.55bn	IDR 16.89bn	IDR 24.61bn	IDR 18.30bn	IDR 17.92bn	IDR 15.23bn	IDR 16.45bn	IDR 16.15bn
Operating income	−IDR 1.25bn	−IDR 450.6m	IDR 7.21bn	IDR 532.0m	−IDR 664.5m	−IDR 2.13bn	IDR 2.02bn	−IDR 350.5m
Net income	−IDR 1.71bn	−IDR 1.32bn	IDR 5.59bn	−IDR 521.6m	−IDR 403.5m	−IDR 1.73bn	IDR 278.5m	−IDR 689.0m
Diluted earnings per share	-1.14	-0.88	4.47	-0.42	-0.32	-1.38	0.22	-0.55
Cash from operations	−IDR 2.16bn	IDR 1.64bn	IDR 5.61bn	IDR 3.59bn	IDR 1.52bn	−IDR 58.0m	IDR 7.73bn	IDR 7.73bn
Capital spending	−IDR 431.0m	−IDR 567.0m	−IDR 218.0m	−IDR 3.26bn	−IDR 2.64bn	−IDR 1.95bn	−IDR 13.92bn	−IDR 13.92bn
Free cash flow	−IDR 2.59bn	IDR 1.07bn	IDR 5.39bn	IDR 334.0m	−IDR 1.13bn	−IDR 2.01bn	−IDR 6.19bn	−IDR 6.19bn
Total assets	IDR 339.37bn	IDR 318.73bn	IDR 318.67bn	IDR 305.64bn	IDR 304.08bn	IDR 304.78bn	IDR 300.02bn	IDR 295.01bn
Cash and short-term investments	IDR 18.20bn	IDR 7.57bn	IDR 9.93bn	IDR 4.48bn	IDR 4.45bn	IDR 6.34bn	IDR 5.17bn	IDR 5.30bn
Debt	IDR 4.36bn	IDR 10.97bn	IDR 86.03bn	IDR 86.46bn	IDR 85.33bn	IDR 85.83bn	IDR 78.86bn	IDR 4.56bn
Shareholders' equity	IDR 230.22bn	IDR 202.67bn	IDR 203.99bn	IDR 193.48bn	IDR 194.00bn	IDR 194.41bn	IDR 196.13bn	IDR 195.71bn

Financial ratios

Data as of 2 Sept 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	43.0%	39.5%	40.7%	45.8%	48.9%	46.9%
Operating margin	3.1%	1.1%	-9.0%	9.4%	27.6%	36.6%
Net margin	1.8%	0.5%	-9.4%	6.6%	21.3%	28.8%
Return on equity	1.4%	0.4%	-7.0%	6.0%	31.9%	53.2%
Return on assets	0.9%	0.2%	-5.0%	5.3%	26.6%	39.7%
Free cash flow yield	6.1%	23.2%	16.9%	9.5%	41.5%	13.2%
Revenue growth	2.2%	11.9%	-24.5%	-36.2%	65.0%	256.8%
Earnings growth	293.0%	-105.5%	-207.8%	-80.3%	22.0%	468.1%
Current ratio	3.30x	3.64x	6.08x	11.28x	5.78x	3.44x
Debt to equity	0.32x	0.30x	0.22x	0.10x	0.05x	0.02x
Equity ratio	64.0%	65.4%	72.0%	87.7%	83.4%	74.7%
Interest coverage	6.55x	1.98x	-27.56x	22.19x	—	—
R&D as a share of sales	0.5%	0.5%	0.2%	0.3%	0.1%	0.3%
Buybacks as a share of market value	0.0%	0.0%	0.0%	0.0%	-25.0%	-92.0%

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	-4.8%	-1.9%	—
Operating income	-34.0%	-40.3%	—
Net income	-38.6%	-43.9%	—

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	41.3%	42.5%	44.8%	—

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021
Price to earnings	78.3	326.1	-22.5	24.1	14.5
Price to sales	1.4	1.5	2.1	1.6	3.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 6 Aug 2021.

	FY2021
Paid in the year	4.80

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Diagnos Laboratorium Utama PT Tbk DGNS.JK · IDR

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology